Monday, 18 Feb 2019

You are here

ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use

The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women.  The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.

Guidelines was developed using the GRADE system, based on a systematic literature review, and focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen.

The American College of Physicians (ACP) strongly recommends bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab for reducing fracture risk in women with osteoporosis. ACP advises physicians to prescribe generics over brand name drugs whenever possible and to discuss medication adherence with their patients, especially for bisphosphonates. 

ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestin therapy or raloxifene for the treatment of osteoporosis in women. Estrogen treatment is associated with serious harms such as increased risk for cerebrovascular accidents and venous thromboembolic events that outweigh the potential benefits.

The evidence suggests that physicians should treat women with osteoporosis with drug therapy for five years. Continuing treatment after the initial five years may be beneficial for some patients and may be appropriate after reassessing the risks and benefits of continuing therapy.

ACP's states the evidence suggests that physicians should treat women with osteoporosis with drug therapy for 5 years. ACP recommends against bone density monitoring during the 5-year treatment period because the evidence does not show any benefit for monitoring during treatment. The evidence also does not support frequent monitoring of women with normal bone density for osteoporosis, as most women with normal bone density measurements did not progress to osteoporosis within 15 years.

Physicians should offer bisphosphonates to reduce the risk for vertebral fractures in men with known osteoporosis. The decision to treat osteopenic women 65 years of age or older who are at a high risk for fracture should be based on a discussion of patient preferences; fracture risk profile; and the benefits, harms, and costs of medications.

Osteoporosis is an enormous public health problem affecting about half of all Americans over the age of 50. The author of an editorial from Oregon Health and Science University in Portland writes that ACP’s recommendation to offer bisphosphonates or denosumab to women with osteoporosis is particularly important because, despite the wealth of evidence, osteoporosis remains underdetected and undertreated. ACP’s guideline provides a solid basis for informed clinical decision-making.

There is an accompanying video from the  ACP’s president discussing treatment of low bone density or osteoporosis are available to download at http://www.dssimon.com/MM/ACP-osteoporosis-guideline/

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Older Men Less Likely to be Assessed and Treated for Osteoporosis

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Hip Replacements Lasting 25 Years

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

In the USA, there is an estimated 400,000 total hip arthroplasties (THA) annually. UK invesigators set out to answer the question: how long does a hip replacement last?

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Vertebroplasty and Kyphoplasty Shown to Be Ineffective

There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF).  Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful means of restoring vertebral height and strength capable of reducing pain in symptomatic patients.

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.